HIV gp160 vaccine - Hyland Immuno
Latest Information Update: 08 Feb 2008
Price :
$50 *
At a glance
- Originator Hyland Immuno
- Class AIDS vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 10 Sep 1999 New profile, split from generic HIV gp160 profile
- 28 Nov 1994 Phase-I clinical trials for HIV-1 infections in USA (Injection)
- 28 Nov 1994 Phase-II clinical trials for HIV-1 infections in Austria (Injection)